The study , published July 15, analyzed the outcomes of more than 10,000 patients hospitalized with COVID-19 in the U.S. Researchers compared the outcomes of similar patients who did and did not use statins or anti-hypertensive medications.
The cholesterol-lowering drugs were associated with a more than 40 percent reduction in in-hospital death and a more than 25 percent reduction in the risk of severe outcome.
Among those who had a history of heart disease or high blood pressure hospitalized with COVID-19, the medications were linked to a 32 percent lower odds of death.
“Early during the pandemic, there were questions as to whether certain cardiovascular medications might worsen COVID-19 infections,” said Lori Daniels, MD, lead study author and director of the cardiovascular intensive care unit at UC San Diego Health. “We found that not only are statins and anti-hypertensive medications safe – they may very well be protective in patients hospitalized for COVID-19, especially among those with a history of hypertension or cardiovascular disease.”
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
